Evidence map›Paper›PMID 31199621›Full record

ArticleACS chemical neuroscience2019

Novel Dimethyltyrosine-Tetrahydroisoquinoline Peptidomimetics with Aromatic Tetrahydroisoquinoline Substitutions Show

Deanna Montgomery, Jessica P Anand, Nicholas W Griggs, Thomas J Fernandez, Joshua G Hartman, Ashley A Sánchez-Santiago, Irina D Pogozheva, John R Traynor, Henry I Mosberg

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Deanna MontgomeryDepartment of Medicinal Chemistry, College of Pharmacy , University of Michigan , Ann Arbor , Michigan 48109 , United States.
Jessica P AnandDepartment of Pharmacology, Medical School , University of Michigan , Ann Arbor , Michigan 48109 , United States.
Nicholas W GriggsDepartment of Pharmacology, Medical School , University of Michigan , Ann Arbor , Michigan 48109 , United States.
Thomas J FernandezDepartment of Pharmacology, Medical School , University of Michigan , Ann Arbor , Michigan 48109 , United States.
Joshua G HartmanDepartment of Pharmacology, Medical School , University of Michigan , Ann Arbor , Michigan 48109 , United States.
Ashley A Sánchez-SantiagoDepartment of Pharmacology, Medical School , University of Michigan , Ann Arbor , Michigan 48109 , United States.
Irina D PogozhevaDepartment of Medicinal Chemistry, College of Pharmacy , University of Michigan , Ann Arbor , Michigan 48109 , United States.
John R TraynorDepartment of Pharmacology, Medical School , University of Michigan , Ann Arbor , Michigan 48109 , United States.
Henry I MosbergDepartment of Medicinal Chemistry, College of Pharmacy , University of Michigan , Ann Arbor , Michigan 48109 , United States.ORCID 0000-0002-4107-8870
University of Michigan · US

Funding

Development of Mixed Function Opioid Peptides and PeptidomimeticsR01DA003910 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MOSBERG, HENRY ISAAC · 1985 to 2017
$9.0M
University of Michigan Postbaccalaureate Research Education Program (UM PREP)R25GM086262 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ALLEN, BENJAMIN · 2009 to 2024
$6.1M
NIDA Training Program in Neuroscience-Administrative SupplementT32DA007281 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Shelly Beth Flagel · 1995 to 2026
$5.7M
Development of Long Lasting Stable Fentanyl Antagonist to Reverse Opioid OverdoseR21DA051732 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ANAND, JESSICA PRIYA · 2020 to 2021
$429k
Examining Novel Fentalogs: Pharmacological Characteristics and ReversibilityR03DA048129 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ANAND, JESSICA PRIYA · 2019 to 2020
$156k
NIDA NIH HHS R01 DA003910NIDA NIH HHS R03 DA048129NIDA NIH HHS R21 DA051732NIDA NIH HHS T32 DA007281NIGMS NIH HHS R25 GM086262
6 · The paper itself

Abstract

The dimethyltyrosine-tetrahydroisoquinoline (Dmt-Tiq) scaffold was originally developed in the production of selective delta opioid receptor (DOR) antagonists. Installation of a 7-benzyl pendant on the tetrahydroisoquinoline core of this classic opioid scaffold introduced kappa opioid receptor (KOR) agonism. Further modification of this pendant resulted in retention of KOR agonism and the addition of mu opioid receptor (MOR) partial agonism, a bifunctional profile with potential to be used in the treatment of cocaine addiction.

Indexed as

AnimalsCell LinePeptidomimeticsRatsReceptors, Opioid, kappaReceptors, Opioid, muStructure-Activity RelationshipTetrahydroisoquinolinesPeptidomimeticsReceptors, Opioid, kappaReceptors, Opioid, muTetrahydroisoquinolinescocaine addictiondimethyltyrosine−tetrahydroisoquinolinemultifunctional ligandsopioidspeptidomimeticssynthesis

Identifiers

PMID31199621
PMCPMC6726392
OpenAlexW2949410231

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.